Worth reading
26Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Deterioration
Direction inferred from the company’s description.Scale
-81
¥ millionWording
Conditional
How definitive the wording is.Contents of this document
Financial results presentation2026年6月期 第1四半期4 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥192 million-29.8%
Operating profit¥-91 million
Ordinary income¥-90 million
Net income¥-97 million
Results for the three months of the current quarter
Net Sales
¥192 million
Operating profit
¥-91 million
Ordinary income
¥-90 million
Profit attributable to owners of the parent
¥-97 million
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
- LSS売上高¥-74 millionFactorsアカデミアの大型案件減少
- FDS売上高¥-40 millionFactors顧客の大型臨床試験スケジュールによる案件減少
- BMS売上高¥33 millionFactors好調な新規受注
- Selling, general and administrative expensesFactors賃上げによる人件費増など
New initiatives
- 短鎖脂肪酸と中鎖脂肪酸の分析に特化した『短中鎖脂肪酸分析』サービスの販売開始
Segment results
- Life Science research support services (LSS)Net Sales¥122 millionYear on year against the same period last year-37.8%
- Functional materials development support services (FDS)Net Sales¥36 millionYear on year against the same period last year-52.6%
- Bio-manufacturing support services (BMS)Net Sales¥33 million
Number of employees
Number of Employees62 people
Reference dateAs of June 2025
| Item | Details |
|---|---|
| Document type | Financial results presentation |
| Fiscal Period Covered | 2026年6月期 第1四半期 |
| Net Sales | ¥192 million (YoY -29.8%) |
| Operating profit | ¥-91 million |
| Ordinary income | ¥-90 million |
| Net income | ¥-97 million |
| Results for the three months of the current quarter | Net Sales ¥192 million / Operating profit ¥-91 million / Ordinary income ¥-90 million / Profit attributable to owners of the parent ¥-97 million |
| Segment results | Segment Life Science research support services (LSS) / Net Sales ¥122 million / Year on year against the same period last year -37.8 % / Profit Not disclosed, Segment Functional materials development support services (FDS) / Net Sales ¥36 million / Year on year against the same period last year -52.6 % / Profit Not disclosed, Segment Bio-manufacturing support services (BMS) / Net Sales ¥33 million / Year on year against the same period last year Not disclosed / Profit Not disclosed |
| Breakdown of Factors Affecting the Change | Factors アカデミアの大型案件減少 / Amount ¥-74 million / Subject LSS売上高, Factors 顧客の大型臨床試験スケジュールによる案件減少 / Amount ¥-40 million / Subject FDS売上高, Factors 好調な新規受注 / Amount ¥33 million / Subject BMS売上高, Factors 賃上げによる人件費増など / Amount Not disclosed / Subject Selling, general and administrative expenses |
| Number of employees | Number of Employees 62 people / Reference date As of June 2025 / Change during the period Not disclosed / Hiring plan Not disclosed |
| New initiatives | 短鎖脂肪酸と中鎖脂肪酸の分析に特化した『短中鎖脂肪酸分析』サービスの販売開始 |
Items this document does not state (20)
Gross Profit MarginOperating profit marginSelling, general and administrative expensesFull-year earnings forecastProgress against full-year forecastSelf-assessment against the planKey KPIsUnit price and quantity metricsNumber of stores and locationsAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.ライフサイエンス研究支援サービスではアカデミアの大型案件が少なく、米国事業も低迷した。機能性素材開発支援サービスでは顧客の臨床試験スケジュールにより大型案件が少なかった。加えて、賃上げによる人件費増などで販売費及び一般管理費が増加した。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.